Clinical trial • Phase IV • Respiratory
OXYGEN for Weaning failure | Weaning of mechanical ventilation
Phase IV trial of OXYGEN for Weaning failure | Weaning of mechanical ventilation.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Weaning failure | Weaning of mechanical ventilation
- Trial Stage
- Phase IV
- Drug Modality
- Other
Key dates
- Initial CTIS Submission Date
- 23-07-2024
- First CTIS Authorization Date
- 07-10-2024
Trial design
Non-Invasive Ventilation (NIV) versus High Flow Oxygen therapy (HFOT); no drug dose or schedule specified-controlled Phase IV trial across 8 sites in Spain.
- Comparator
- Non-Invasive Ventilation (NIV) versus High Flow Oxygen therapy (HFOT); no drug dose or schedule specified
- Target Sample Size
- 260
Eligibility
Recruits 260 No vulnerable populations selected (isVulnerablePopulationSelected: false). Consent/assent handling not specified in available data..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected: false). Consent/assent handling not specified in available data.
Inclusion criteria
- {"criterion_text":"- Age ≥ 65 years\n- Body mass index (BMI)>30\n- Chronic obstructive pulmonary disease (COPD) or asthma as a cause of invasive mechanical ventilation\n- Cardiac failure as a cause of intubation or history of ejection fraction <= 30%\n- Acute Physiology and Chronic Health Evaluation (APACHE II) > 12 at the time of extubation\n- Time of mechanical ventilation > 7 days\n- Positive water balance\n- Difficult or prolonged weaning\n- Pneumonia (or any medical pathology over surgical) as a cause of ARF\n- Hypercapnia (paCO2 > 45 mmHg) at the time of extubation\n- Ineffective cough\n- Abundant secretions"}
Exclusion criteria
- {"criterion_text":"- Structural neurologic disease\n- Not intubation order\n- Life support therapy limitation\n- Tracheotomized\n- Spinal cord injury\n- Scheduled surgical intervention in the next 48 hours post-extubation\n- Re-admission\n- Transfer to another center\n- Refusal of the patient or relatives\n- Direct extubation without performing a spontaneous breathing trial\n- Contraindication to apply NIV or high flow oxygen"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Acute respiratory failure within 48 hours after extubation","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- Intubation\n- Nosocomial infection\n- Tracheotomy\n- Organ failure\n- ICU Mortality\n- Hospital mortality\n- 28-day mortality\n- ICU length of stay\n- Hospital length of stay\n- Duration of mechanical ventilation","definition_or_measurement_approach":""}
Recruitment
- Planned Sample Size
- 260
- Recruitment Window Months
- 36
- Consent Approach
- Informed consent required; subject information and informed consent form available (document L1_HIP_General_v1). No details on assent, age-specific documents, or languages specified in the available data.
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 260
Spain
- Earliest CTIS Part Ii Submission Date
- 05-06-2024
- Latest Decision Or Authorization Date
- 14-01-2025
- Processing Time Days
- 223
- Number Of Sites
- 8
- Number Of Participants
- 260
Sites
- Site Name
- Hospital De Tortosa Verge De La Cinta
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Pablo Concha Martínez
- Principal Investigator Email
- pconcha.ebre.ics@gencat.cat
- Contact Person Name
- Pablo Concha Martínez
- Contact Person Email
- pconcha.ebre.ics@gencat.cat
- Site Name
- Hospital De Manises
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Juan Antonio Fernandez Cabrera
- Principal Investigator Email
- juanantoniofernandezcabrera@gmail.com
- Contact Person Name
- Juan Antonio Fernandez Cabrera
- Contact Person Email
- juanantoniofernandezcabrera@gmail.com
- Site Name
- Hospital Francesc De Borja De Gandía
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Susana Isabel Gil García
- Principal Investigator Email
- gil_susgar@gva.es
- Contact Person Name
- Susana Isabel Gil García
- Contact Person Email
- gil_susgar@gva.es
- Site Name
- Consorcio Hospitalario Provincial De Castellon
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Manuel Cubedo Bort
- Principal Investigator Email
- cubedomanuel@gmail.com
- Contact Person Name
- Manuel Cubedo Bort
- Contact Person Email
- cubedomanuel@gmail.com
- Site Name
- Hospital De Sagunto
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Adrian Quinza Real
- Principal Investigator Email
- quinza_jos@gva.es
- Contact Person Name
- Adrian Quinza Real
- Contact Person Email
- quinza_jos@gva.es
- Site Name
- Hospital Arnau De Vilanova De Valencia
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Amparo Navarro Eduardo
- Principal Investigator Email
- amparonavarroeduardo@gmail.com
- Contact Person Name
- Amparo Navarro Eduardo
- Contact Person Email
- amparonavarroeduardo@gmail.com
- Site Name
- Hospital General Universitario De Castellon
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Francisco Bernal Julian
- Principal Investigator Email
- bernaljulianpaco@gmail.com
- Contact Person Name
- Francisco Bernal Julian
- Contact Person Email
- bernaljulianpaco@gmail.com
- Site Name
- Hospital Universitario Dr Peset Aleixandre
- Department Name
- Intensive Care Unit
- Principal Investigator Name
- Alberto Belenguer Muncharaz
- Principal Investigator Email
- belengueralberto8@gmail.com
- Contact Person Name
- Alberto Belenguer Muncharaz
- Contact Person Email
- belengueralberto8@gmail.com
Sponsor
Primary sponsor
- Full Name
- Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
- Organisation Type
- Patient organisation/association
- Country Of Registered Address
- Spain
Third parties
- {"country":"","full_name":"Fundacion FISABIO","duties_or_roles":"Source of monetary support","organisation_type":""}
- {"country":"","full_name":"Hospital Universitario Doctor Peset","duties_or_roles":"Source of monetary support","organisation_type":""}
- {"country":"Spain","full_name":"AIR LIQUIDE SANTE INTERNATIONAL","duties_or_roles":"Product manufacturer / marketing authorisation holder for investigational product","organisation_type":""}
Investigational products
- Investigational Product Name
- Oxígeno Medicinal Líquido Air Liquide 99,5% v/v, gas criogénico medicinal en recipientes fijos.
- Active Substance
- OXYGEN
- Modality
- Other
- Routes Of Administration
- INHALATION GAS
- Route
- INHALATION GAS
- Authorisation Status
- Marketing authorised (marketingAuthNumber: 66974)
- Maximum Dose
- 100 percent
Related trials
Other published trials that may interest you.
- phospholipid fraction, bovine lung for Idiopathic pulmonary fibrosis
- Allogeneic bone marrow-derived mesenchymal adult stromal cells, ex-vivo expanded for Chronic lung allograft dysfunction (CLAD) | Bronchiolitis obliterans syndrome (BOS) in lung transplant recipients
- IVX-121; HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN for Respiratory syncytial virus infection | Human metapneumovirus infection
- Lyophilized bacterial lysates of: Haemophilus influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Moraxella (Branhamella/Neisseria) catarrhalis (OM-85) for Respiratory tract infections with wheezing lower respiratory illness
- Roginolisib for Advanced non-squamous non-small cell lung cancer